Medicare limits payments for new Alzheimer’s drug to clinical trials
Medicare coverage for a costly, but controversial, new Alzheimer’s drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication. View original article Contributor: Lenny Bernstein